Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Kathrine Lederballe Grøn; Elizabeth V Arkema; Bente Glintborg; Frank Mehnert; Mikkel Østergaard; Lene Dreyer; Mette Nørgaard; Niels Steen Krogh; Johan Askling; Merete Lund Hetland

doi:10.1136/annrheumdis-2018-214326

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Rheumatoid arthritis

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Grøn KL, Arkema EV, Glintborg B The ARTIS Study Group, et al

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Annals of the Rheumatic Diseases 2019;78:320-327.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password